nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimetrexate—DHFR—prostate gland—prostate cancer	0.0148	0.224	CbGeAlD
Trimetrexate—DHFR—seminal vesicle—prostate cancer	0.0125	0.189	CbGeAlD
Trimetrexate—DHFR—renal system—prostate cancer	0.0101	0.152	CbGeAlD
Trimetrexate—DHFR—urethra—prostate cancer	0.0099	0.15	CbGeAlD
Trimetrexate—Trimethoprim—TYMS—prostate cancer	0.00864	0.766	CrCbGaD
Trimetrexate—DHFR—bone marrow—prostate cancer	0.00762	0.115	CbGeAlD
Trimetrexate—DHFR—testis—prostate cancer	0.00651	0.0985	CbGeAlD
Trimetrexate—DHFR—lymph node—prostate cancer	0.00472	0.0714	CbGeAlD
Trimetrexate—Thrombocytopenia—Flutamide—prostate cancer	0.00291	0.0051	CcSEcCtD
Trimetrexate—Anaemia—Cabazitaxel—prostate cancer	0.00285	0.00499	CcSEcCtD
Trimetrexate—Blood creatinine increased—Conjugated Estrogens—prostate cancer	0.00283	0.00496	CcSEcCtD
Trimetrexate—Fatigue—Abiraterone—prostate cancer	0.00282	0.00494	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Estradiol—prostate cancer	0.00278	0.00488	CcSEcCtD
Trimetrexate—Hepatotoxicity—Docetaxel—prostate cancer	0.00278	0.00487	CcSEcCtD
Trimetrexate—Hepatotoxicity—Capecitabine—prostate cancer	0.00269	0.00472	CcSEcCtD
Trimetrexate—Trimethoprim—CYP3A4—prostate cancer	0.00263	0.233	CrCbGaD
Trimetrexate—Body temperature increased—Abiraterone—prostate cancer	0.00258	0.00453	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Etoposide—prostate cancer	0.00258	0.00453	CcSEcCtD
Trimetrexate—Fatigue—Flutamide—prostate cancer	0.00256	0.00449	CcSEcCtD
Trimetrexate—Confusional state—Cabazitaxel—prostate cancer	0.00253	0.00444	CcSEcCtD
Trimetrexate—Feeling abnormal—Nilutamide—prostate cancer	0.00246	0.00431	CcSEcCtD
Trimetrexate—Thrombocytopenia—Cabazitaxel—prostate cancer	0.00246	0.00431	CcSEcCtD
Trimetrexate—Feeling abnormal—Flutamide—prostate cancer	0.00245	0.0043	CcSEcCtD
Trimetrexate—Anaemia—Bicalutamide—prostate cancer	0.00244	0.00428	CcSEcCtD
Trimetrexate—Fatigue—Estradiol valerate/Dienogest—prostate cancer	0.00242	0.00424	CcSEcCtD
Trimetrexate—Pruritus—Estramustine—prostate cancer	0.00238	0.00418	CcSEcCtD
Trimetrexate—Body temperature increased—Nilutamide—prostate cancer	0.00236	0.00414	CcSEcCtD
Trimetrexate—Serum creatinine increased—Epirubicin—prostate cancer	0.00235	0.00413	CcSEcCtD
Trimetrexate—Asthenia—Abiraterone—prostate cancer	0.00235	0.00411	CcSEcCtD
Trimetrexate—Fatigue—Degarelix—prostate cancer	0.0023	0.00403	CcSEcCtD
Trimetrexate—Pruritus—Estrone—prostate cancer	0.00228	0.00399	CcSEcCtD
Trimetrexate—Hypocalcaemia—Capecitabine—prostate cancer	0.00227	0.00398	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Docetaxel—prostate cancer	0.00227	0.00398	CcSEcCtD
Trimetrexate—Hyponatraemia—Mitoxantrone—prostate cancer	0.00226	0.00397	CcSEcCtD
Trimetrexate—Feeling abnormal—Degarelix—prostate cancer	0.0022	0.00385	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Capecitabine—prostate cancer	0.0022	0.00385	CcSEcCtD
Trimetrexate—Serum creatinine increased—Doxorubicin—prostate cancer	0.00218	0.00382	CcSEcCtD
Trimetrexate—Confusional state—Bicalutamide—prostate cancer	0.00217	0.00381	CcSEcCtD
Trimetrexate—Fatigue—Cabazitaxel—prostate cancer	0.00217	0.0038	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Etoposide—prostate cancer	0.00216	0.00378	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Docetaxel—prostate cancer	0.00215	0.00376	CcSEcCtD
Trimetrexate—Asthenia—Nilutamide—prostate cancer	0.00214	0.00376	CcSEcCtD
Trimetrexate—Vomiting—Estramustine—prostate cancer	0.00214	0.00375	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Estradiol—prostate cancer	0.00213	0.00374	CcSEcCtD
Trimetrexate—Asthenia—Flutamide—prostate cancer	0.00213	0.00374	CcSEcCtD
Trimetrexate—Rash—Estramustine—prostate cancer	0.00212	0.00372	CcSEcCtD
Trimetrexate—Dermatitis—Estramustine—prostate cancer	0.00212	0.00372	CcSEcCtD
Trimetrexate—Pruritus—Nilutamide—prostate cancer	0.00211	0.0037	CcSEcCtD
Trimetrexate—Blood creatinine increased—Mitoxantrone—prostate cancer	0.00211	0.0037	CcSEcCtD
Trimetrexate—Thrombocytopenia—Bicalutamide—prostate cancer	0.00211	0.0037	CcSEcCtD
Trimetrexate—Body temperature increased—Degarelix—prostate cancer	0.00211	0.0037	CcSEcCtD
Trimetrexate—Pruritus—Flutamide—prostate cancer	0.0021	0.00369	CcSEcCtD
Trimetrexate—Vomiting—Abiraterone—prostate cancer	0.00208	0.00364	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Capecitabine—prostate cancer	0.00208	0.00364	CcSEcCtD
Trimetrexate—Feeling abnormal—Cabazitaxel—prostate cancer	0.00207	0.00363	CcSEcCtD
Trimetrexate—Rash—Abiraterone—prostate cancer	0.00206	0.00361	CcSEcCtD
Trimetrexate—Dermatitis—Abiraterone—prostate cancer	0.00206	0.00361	CcSEcCtD
Trimetrexate—Vomiting—Estrone—prostate cancer	0.00204	0.00358	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Mitoxantrone—prostate cancer	0.00203	0.00356	CcSEcCtD
Trimetrexate—Rash—Estrone—prostate cancer	0.00203	0.00355	CcSEcCtD
Trimetrexate—Dermatitis—Estrone—prostate cancer	0.00203	0.00355	CcSEcCtD
Trimetrexate—Asthenia—Estradiol valerate/Dienogest—prostate cancer	0.00201	0.00353	CcSEcCtD
Trimetrexate—Nausea—Estramustine—prostate cancer	0.002	0.00351	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Mitoxantrone—prostate cancer	0.00199	0.00349	CcSEcCtD
Trimetrexate—Body temperature increased—Cabazitaxel—prostate cancer	0.00199	0.00348	CcSEcCtD
Trimetrexate—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.00199	0.00348	CcSEcCtD
Trimetrexate—Asthenia—Degarelix—prostate cancer	0.00191	0.00336	CcSEcCtD
Trimetrexate—Nausea—Estrone—prostate cancer	0.00191	0.00335	CcSEcCtD
Trimetrexate—Vomiting—Nilutamide—prostate cancer	0.0019	0.00333	CcSEcCtD
Trimetrexate—Vomiting—Flutamide—prostate cancer	0.00189	0.00331	CcSEcCtD
Trimetrexate—Pruritus—Degarelix—prostate cancer	0.00189	0.00331	CcSEcCtD
Trimetrexate—Rash—Nilutamide—prostate cancer	0.00188	0.0033	CcSEcCtD
Trimetrexate—Dermatitis—Nilutamide—prostate cancer	0.00188	0.0033	CcSEcCtD
Trimetrexate—Rash—Flutamide—prostate cancer	0.00187	0.00329	CcSEcCtD
Trimetrexate—Dermatitis—Flutamide—prostate cancer	0.00187	0.00328	CcSEcCtD
Trimetrexate—Fatigue—Bicalutamide—prostate cancer	0.00186	0.00326	CcSEcCtD
Trimetrexate—Neutropenia—Mitoxantrone—prostate cancer	0.00182	0.00319	CcSEcCtD
Trimetrexate—Asthenia—Cabazitaxel—prostate cancer	0.0018	0.00316	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Docetaxel—prostate cancer	0.00179	0.00314	CcSEcCtD
Trimetrexate—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.00178	0.00313	CcSEcCtD
Trimetrexate—Feeling abnormal—Bicalutamide—prostate cancer	0.00178	0.00311	CcSEcCtD
Trimetrexate—Nausea—Nilutamide—prostate cancer	0.00177	0.00311	CcSEcCtD
Trimetrexate—Rash—Estradiol valerate/Dienogest—prostate cancer	0.00177	0.0031	CcSEcCtD
Trimetrexate—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.00177	0.0031	CcSEcCtD
Trimetrexate—Nausea—Flutamide—prostate cancer	0.00177	0.0031	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Capecitabine—prostate cancer	0.00173	0.00304	CcSEcCtD
Trimetrexate—Body temperature increased—Bicalutamide—prostate cancer	0.0017	0.00299	CcSEcCtD
Trimetrexate—Anaemia—Goserelin—prostate cancer	0.0017	0.00298	CcSEcCtD
Trimetrexate—Vomiting—Degarelix—prostate cancer	0.0017	0.00297	CcSEcCtD
Trimetrexate—Rash—Degarelix—prostate cancer	0.00168	0.00295	CcSEcCtD
Trimetrexate—Dermatitis—Degarelix—prostate cancer	0.00168	0.00295	CcSEcCtD
Trimetrexate—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00167	0.00292	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Etoposide—prostate cancer	0.00165	0.0029	CcSEcCtD
Trimetrexate—Vomiting—Cabazitaxel—prostate cancer	0.0016	0.0028	CcSEcCtD
Trimetrexate—Convulsion—Goserelin—prostate cancer	0.00159	0.00279	CcSEcCtD
Trimetrexate—Nausea—Degarelix—prostate cancer	0.00158	0.00278	CcSEcCtD
Trimetrexate—Hypocalcaemia—Epirubicin—prostate cancer	0.00158	0.00277	CcSEcCtD
Trimetrexate—Convulsion—Conjugated Estrogens—prostate cancer	0.00158	0.00276	CcSEcCtD
Trimetrexate—Fatigue—Ethinyl Estradiol—prostate cancer	0.00157	0.00275	CcSEcCtD
Trimetrexate—Hyponatraemia—Docetaxel—prostate cancer	0.00156	0.00274	CcSEcCtD
Trimetrexate—Asthenia—Bicalutamide—prostate cancer	0.00155	0.00271	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Epirubicin—prostate cancer	0.00153	0.00268	CcSEcCtD
Trimetrexate—Pruritus—Bicalutamide—prostate cancer	0.00153	0.00267	CcSEcCtD
Trimetrexate—Neutropenia—Etoposide—prostate cancer	0.00152	0.00266	CcSEcCtD
Trimetrexate—Hyponatraemia—Capecitabine—prostate cancer	0.00151	0.00266	CcSEcCtD
Trimetrexate—Confusional state—Goserelin—prostate cancer	0.00151	0.00265	CcSEcCtD
Trimetrexate—Feeling abnormal—Ethinyl Estradiol—prostate cancer	0.0015	0.00263	CcSEcCtD
Trimetrexate—Nausea—Cabazitaxel—prostate cancer	0.00149	0.00262	CcSEcCtD
Trimetrexate—Thrombocytopenia—Goserelin—prostate cancer	0.00147	0.00257	CcSEcCtD
Trimetrexate—Hypocalcaemia—Doxorubicin—prostate cancer	0.00146	0.00257	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Epirubicin—prostate cancer	0.00145	0.00254	CcSEcCtD
Trimetrexate—Body temperature increased—Ethinyl Estradiol—prostate cancer	0.00144	0.00253	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Doxorubicin—prostate cancer	0.00142	0.00248	CcSEcCtD
Trimetrexate—Blood creatinine increased—Capecitabine—prostate cancer	0.00141	0.00248	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—ATM—prostate cancer	0.00141	0.004	CbGpPWpGaD
Trimetrexate—Aspartate aminotransferase increased—Docetaxel—prostate cancer	0.0014	0.00246	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—PCNT—prostate cancer	0.00139	0.00395	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—USO1—prostate cancer	0.00139	0.00395	CbGpPWpGaD
Trimetrexate—Alanine aminotransferase increased—Docetaxel—prostate cancer	0.00137	0.00241	CcSEcCtD
Trimetrexate—Vomiting—Bicalutamide—prostate cancer	0.00137	0.0024	CcSEcCtD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—prostate cancer	0.00137	0.00388	CbGpPWpGaD
Trimetrexate—Rash—Bicalutamide—prostate cancer	0.00136	0.00238	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Capecitabine—prostate cancer	0.00136	0.00238	CcSEcCtD
Trimetrexate—Dermatitis—Bicalutamide—prostate cancer	0.00136	0.00238	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—INS—prostate cancer	0.00135	0.00385	CbGpPWpGaD
Trimetrexate—Phosphatase alkaline increased—Doxorubicin—prostate cancer	0.00134	0.00235	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Capecitabine—prostate cancer	0.00133	0.00233	CcSEcCtD
Trimetrexate—Asthenia—Ethinyl Estradiol—prostate cancer	0.00131	0.00229	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—TYMS—prostate cancer	0.0013	0.00371	CbGpPWpGaD
Trimetrexate—Fatigue—Goserelin—prostate cancer	0.00129	0.00227	CcSEcCtD
Trimetrexate—Pruritus—Ethinyl Estradiol—prostate cancer	0.00129	0.00226	CcSEcCtD
Trimetrexate—Fatigue—Conjugated Estrogens—prostate cancer	0.00128	0.00225	CcSEcCtD
Trimetrexate—Nausea—Bicalutamide—prostate cancer	0.00128	0.00225	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CCND2—prostate cancer	0.00128	0.00363	CbGpPWpGaD
Trimetrexate—Neutropenia—Docetaxel—prostate cancer	0.00126	0.00221	CcSEcCtD
Trimetrexate—Anaemia—Mitoxantrone—prostate cancer	0.00125	0.0022	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—SERPINE1—prostate cancer	0.00124	0.00353	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Goserelin—prostate cancer	0.00124	0.00217	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—CREBBP—prostate cancer	0.00122	0.00348	CbGpPWpGaD
Trimetrexate—Neutropenia—Capecitabine—prostate cancer	0.00122	0.00214	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Epirubicin—prostate cancer	0.00121	0.00212	CcSEcCtD
Trimetrexate—Confusional state—Estradiol—prostate cancer	0.0012	0.0021	CcSEcCtD
Trimetrexate—Body temperature increased—Goserelin—prostate cancer	0.00119	0.00208	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Prednisone—prostate cancer	0.00119	0.00208	CcSEcCtD
Trimetrexate—Convulsion—Mitoxantrone—prostate cancer	0.00118	0.00206	CcSEcCtD
Trimetrexate—Body temperature increased—Conjugated Estrogens—prostate cancer	0.00117	0.00206	CcSEcCtD
Trimetrexate—Vomiting—Ethinyl Estradiol—prostate cancer	0.00116	0.00203	CcSEcCtD
Trimetrexate—Rash—Ethinyl Estradiol—prostate cancer	0.00115	0.00201	CcSEcCtD
Trimetrexate—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00115	0.00201	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—SERPINE1—prostate cancer	0.00115	0.00326	CbGpPWpGaD
Trimetrexate—DHFR—Fluoropyrimidine Activity—TP53—prostate cancer	0.00113	0.0032	CbGpPWpGaD
Trimetrexate—Blood alkaline phosphatase increased—Doxorubicin—prostate cancer	0.00112	0.00196	CcSEcCtD
Trimetrexate—Confusional state—Mitoxantrone—prostate cancer	0.00112	0.00196	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—TYMS—prostate cancer	0.0011	0.00312	CbGpPWpGaD
Trimetrexate—Neutropenia—Prednisone—prostate cancer	0.00109	0.0019	CcSEcCtD
Trimetrexate—Thrombocytopenia—Mitoxantrone—prostate cancer	0.00108	0.0019	CcSEcCtD
Trimetrexate—Nausea—Ethinyl Estradiol—prostate cancer	0.00108	0.0019	CcSEcCtD
Trimetrexate—Asthenia—Goserelin—prostate cancer	0.00108	0.00189	CcSEcCtD
Trimetrexate—Asthenia—Conjugated Estrogens—prostate cancer	0.00107	0.00187	CcSEcCtD
Trimetrexate—Pruritus—Goserelin—prostate cancer	0.00106	0.00186	CcSEcCtD
Trimetrexate—Hyponatraemia—Epirubicin—prostate cancer	0.00106	0.00185	CcSEcCtD
Trimetrexate—Pruritus—Conjugated Estrogens—prostate cancer	0.00105	0.00184	CcSEcCtD
Trimetrexate—Anaemia—Etoposide—prostate cancer	0.00104	0.00183	CcSEcCtD
Trimetrexate—Fatigue—Estradiol—prostate cancer	0.00103	0.0018	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—IL2—prostate cancer	0.00101	0.00286	CbGpPWpGaD
Trimetrexate—Blood creatinine increased—Epirubicin—prostate cancer	0.000985	0.00173	CcSEcCtD
Trimetrexate—Feeling abnormal—Estradiol—prostate cancer	0.00098	0.00172	CcSEcCtD
Trimetrexate—Convulsion—Etoposide—prostate cancer	0.000978	0.00172	CcSEcCtD
Trimetrexate—Hyponatraemia—Doxorubicin—prostate cancer	0.000976	0.00171	CcSEcCtD
Trimetrexate—Fatigue—Mitoxantrone—prostate cancer	0.000955	0.00167	CcSEcCtD
Trimetrexate—Vomiting—Goserelin—prostate cancer	0.000954	0.00167	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—CDKN1B—prostate cancer	0.000949	0.0027	CbGpPWpGaD
Trimetrexate—Aspartate aminotransferase increased—Epirubicin—prostate cancer	0.000947	0.00166	CcSEcCtD
Trimetrexate—Rash—Goserelin—prostate cancer	0.000946	0.00166	CcSEcCtD
Trimetrexate—Dermatitis—Goserelin—prostate cancer	0.000945	0.00166	CcSEcCtD
Trimetrexate—Vomiting—Conjugated Estrogens—prostate cancer	0.000945	0.00166	CcSEcCtD
Trimetrexate—Body temperature increased—Estradiol—prostate cancer	0.00094	0.00165	CcSEcCtD
Trimetrexate—Rash—Conjugated Estrogens—prostate cancer	0.000937	0.00164	CcSEcCtD
Trimetrexate—Dermatitis—Conjugated Estrogens—prostate cancer	0.000936	0.00164	CcSEcCtD
Trimetrexate—Confusional state—Etoposide—prostate cancer	0.000929	0.00163	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Epirubicin—prostate cancer	0.000927	0.00163	CcSEcCtD
Trimetrexate—Feeling abnormal—Mitoxantrone—prostate cancer	0.000913	0.0016	CcSEcCtD
Trimetrexate—Blood creatinine increased—Doxorubicin—prostate cancer	0.000911	0.0016	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—MDM2—prostate cancer	0.000903	0.00257	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Etoposide—prostate cancer	0.000902	0.00158	CcSEcCtD
Trimetrexate—Nausea—Goserelin—prostate cancer	0.000891	0.00156	CcSEcCtD
Trimetrexate—Nausea—Conjugated Estrogens—prostate cancer	0.000883	0.00155	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—CDKN1A—prostate cancer	0.000876	0.00249	CbGpPWpGaD
Trimetrexate—Body temperature increased—Mitoxantrone—prostate cancer	0.000876	0.00154	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	0.000876	0.00154	CcSEcCtD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—prostate cancer	0.000871	0.00247	CbGpPWpGaD
Trimetrexate—Anaemia—Docetaxel—prostate cancer	0.000867	0.00152	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Doxorubicin—prostate cancer	0.000858	0.0015	CcSEcCtD
Trimetrexate—Asthenia—Estradiol—prostate cancer	0.000853	0.0015	CcSEcCtD
Trimetrexate—Neutropenia—Epirubicin—prostate cancer	0.000849	0.00149	CcSEcCtD
Trimetrexate—Pruritus—Estradiol—prostate cancer	0.000841	0.00147	CcSEcCtD
Trimetrexate—Anaemia—Capecitabine—prostate cancer	0.00084	0.00147	CcSEcCtD
Trimetrexate—DHFR—Metabolism—HAO1—prostate cancer	0.000838	0.00238	CbGpPWpGaD
Trimetrexate—DHFR—E2F transcription factor network—EP300—prostate cancer	0.000833	0.00237	CbGpPWpGaD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CDKN1B—prostate cancer	0.000825	0.00234	CbGpPWpGaD
Trimetrexate—Convulsion—Docetaxel—prostate cancer	0.000813	0.00143	CcSEcCtD
Trimetrexate—Asthenia—Mitoxantrone—prostate cancer	0.000795	0.00139	CcSEcCtD
Trimetrexate—Fatigue—Etoposide—prostate cancer	0.000795	0.00139	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CCND1—prostate cancer	0.000787	0.00223	CbGpPWpGaD
Trimetrexate—Neutropenia—Doxorubicin—prostate cancer	0.000786	0.00138	CcSEcCtD
Trimetrexate—Confusional state—Docetaxel—prostate cancer	0.000772	0.00135	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CDKN1A—prostate cancer	0.000761	0.00216	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Etoposide—prostate cancer	0.000759	0.00133	CcSEcCtD
Trimetrexate—DHFR—Disease—SV2B—prostate cancer	0.000758	0.00215	CbGpPWpGaD
Trimetrexate—Vomiting—Estradiol—prostate cancer	0.000756	0.00133	CcSEcCtD
Trimetrexate—Thrombocytopenia—Docetaxel—prostate cancer	0.00075	0.00131	CcSEcCtD
Trimetrexate—Rash—Estradiol—prostate cancer	0.00075	0.00131	CcSEcCtD
Trimetrexate—Dermatitis—Estradiol—prostate cancer	0.000749	0.00131	CcSEcCtD
Trimetrexate—Anaemia—Prednisone—prostate cancer	0.000748	0.00131	CcSEcCtD
Trimetrexate—Confusional state—Capecitabine—prostate cancer	0.000748	0.00131	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—HIST1H2BG—prostate cancer	0.000745	0.00212	CbGpPWpGaD
Trimetrexate—Body temperature increased—Etoposide—prostate cancer	0.000729	0.00128	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—MYC—prostate cancer	0.000726	0.00206	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Capecitabine—prostate cancer	0.000726	0.00127	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—HIST1H4H—prostate cancer	0.000719	0.00204	CbGpPWpGaD
Trimetrexate—DHFR—Disease—RFK—prostate cancer	0.000713	0.00202	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PGAM2—prostate cancer	0.000713	0.00202	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NAGLU—prostate cancer	0.000713	0.00202	CbGpPWpGaD
Trimetrexate—DHFR—Disease—AOX1—prostate cancer	0.000713	0.00202	CbGpPWpGaD
Trimetrexate—Nausea—Estradiol—prostate cancer	0.000706	0.00124	CcSEcCtD
Trimetrexate—Vomiting—Mitoxantrone—prostate cancer	0.000704	0.00123	CcSEcCtD
Trimetrexate—Convulsion—Prednisone—prostate cancer	0.000701	0.00123	CcSEcCtD
Trimetrexate—Rash—Mitoxantrone—prostate cancer	0.000699	0.00122	CcSEcCtD
Trimetrexate—Dermatitis—Mitoxantrone—prostate cancer	0.000698	0.00122	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—CDKN1B—prostate cancer	0.000689	0.00196	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PSAT1—prostate cancer	0.000683	0.00194	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—TST—prostate cancer	0.000683	0.00194	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CSAD—prostate cancer	0.000683	0.00194	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GRHL1—prostate cancer	0.000683	0.00194	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CBR1—prostate cancer	0.000683	0.00194	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ADI1—prostate cancer	0.000683	0.00194	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—MAD1L1—prostate cancer	0.000676	0.00192	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—HIST1H2BG—prostate cancer	0.000666	0.00189	CbGpPWpGaD
Trimetrexate—Asthenia—Etoposide—prostate cancer	0.000661	0.00116	CcSEcCtD
Trimetrexate—Fatigue—Docetaxel—prostate cancer	0.00066	0.00116	CcSEcCtD
Trimetrexate—Nausea—Mitoxantrone—prostate cancer	0.000658	0.00115	CcSEcCtD
Trimetrexate—Pruritus—Etoposide—prostate cancer	0.000652	0.00114	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—TP53—prostate cancer	0.000647	0.00184	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HSD17B1—prostate cancer	0.000645	0.00183	CbGpPWpGaD
Trimetrexate—DHFR—Disease—DNAJC3—prostate cancer	0.000645	0.00183	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CTBP2—prostate cancer	0.000645	0.00183	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—HIST1H4H—prostate cancer	0.000643	0.00183	CbGpPWpGaD
Trimetrexate—Fatigue—Capecitabine—prostate cancer	0.000639	0.00112	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—CDKN1A—prostate cancer	0.000636	0.0018	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—UGT2B17—prostate cancer	0.000635	0.0018	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—UGT2B15—prostate cancer	0.000635	0.0018	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CKMT2—prostate cancer	0.000635	0.0018	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GRHPR—prostate cancer	0.000635	0.0018	CbGpPWpGaD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—prostate cancer	0.000631	0.00179	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Docetaxel—prostate cancer	0.000631	0.00111	CcSEcCtD
Trimetrexate—Feeling abnormal—Capecitabine—prostate cancer	0.000611	0.00107	CcSEcCtD
Trimetrexate—Body temperature increased—Docetaxel—prostate cancer	0.000605	0.00106	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—MAD1L1—prostate cancer	0.000605	0.00172	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—AOX1—prostate cancer	0.000597	0.0017	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GSTM3—prostate cancer	0.000597	0.0017	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—RFK—prostate cancer	0.000597	0.0017	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PGAM2—prostate cancer	0.000597	0.0017	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—NAGLU—prostate cancer	0.000597	0.0017	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SULT2B1—prostate cancer	0.000597	0.0017	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—MBTPS1—prostate cancer	0.000597	0.0017	CbGpPWpGaD
Trimetrexate—DHFR—Folate Metabolism—IL6—prostate cancer	0.000592	0.00168	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—TOP2A—prostate cancer	0.000586	0.00167	CbGpPWpGaD
Trimetrexate—Body temperature increased—Capecitabine—prostate cancer	0.000586	0.00103	CcSEcCtD
Trimetrexate—Vomiting—Etoposide—prostate cancer	0.000586	0.00103	CcSEcCtD
Trimetrexate—Anaemia—Epirubicin—prostate cancer	0.000585	0.00103	CcSEcCtD
Trimetrexate—Rash—Etoposide—prostate cancer	0.000581	0.00102	CcSEcCtD
Trimetrexate—Dermatitis—Etoposide—prostate cancer	0.000581	0.00102	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN1B—prostate cancer	0.00058	0.00165	CbGpPWpGaD
Trimetrexate—DHFR—Disease—IL17RD—prostate cancer	0.000575	0.00163	CbGpPWpGaD
Trimetrexate—DHFR—Disease—B4GALT4—prostate cancer	0.000575	0.00163	CbGpPWpGaD
Trimetrexate—Fatigue—Prednisone—prostate cancer	0.000569	0.000998	CcSEcCtD
Trimetrexate—DHFR—Metabolism—AMACR—prostate cancer	0.000566	0.00161	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP3A43—prostate cancer	0.000566	0.00161	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—NAT1—prostate cancer	0.000566	0.00161	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SRD5A2—prostate cancer	0.000566	0.00161	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—DEGS1—prostate cancer	0.000566	0.00161	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—AURKA—prostate cancer	0.000559	0.00159	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—NBN—prostate cancer	0.000556	0.00158	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CCND1—prostate cancer	0.000554	0.00157	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MLH1—prostate cancer	0.000553	0.00157	CbGpPWpGaD
Trimetrexate—Asthenia—Docetaxel—prostate cancer	0.00055	0.000963	CcSEcCtD
Trimetrexate—Convulsion—Epirubicin—prostate cancer	0.000548	0.000961	CcSEcCtD
Trimetrexate—Nausea—Etoposide—prostate cancer	0.000547	0.00096	CcSEcCtD
Trimetrexate—Feeling abnormal—Prednisone—prostate cancer	0.000544	0.000954	CcSEcCtD
Trimetrexate—Pruritus—Docetaxel—prostate cancer	0.000542	0.00095	CcSEcCtD
Trimetrexate—Anaemia—Doxorubicin—prostate cancer	0.000541	0.000949	CcSEcCtD
Trimetrexate—DHFR—Metabolism—HSD17B1—prostate cancer	0.00054	0.00153	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN1A—prostate cancer	0.000536	0.00152	CbGpPWpGaD
Trimetrexate—Asthenia—Capecitabine—prostate cancer	0.000532	0.000933	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—MYC—prostate cancer	0.000527	0.0015	CbGpPWpGaD
Trimetrexate—Pruritus—Capecitabine—prostate cancer	0.000525	0.00092	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—TOP2A—prostate cancer	0.000524	0.00149	CbGpPWpGaD
Trimetrexate—Body temperature increased—Prednisone—prostate cancer	0.000522	0.000915	CcSEcCtD
Trimetrexate—Confusional state—Epirubicin—prostate cancer	0.000521	0.000913	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—prostate cancer	0.000518	0.00147	CbGpPWpGaD
Trimetrexate—DHFR—Disease—WNT4—prostate cancer	0.000512	0.00145	CbGpPWpGaD
Trimetrexate—Convulsion—Doxorubicin—prostate cancer	0.000507	0.00089	CcSEcCtD
Trimetrexate—Thrombocytopenia—Epirubicin—prostate cancer	0.000506	0.000887	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—AURKA—prostate cancer	0.0005	0.00142	CbGpPWpGaD
Trimetrexate—Vomiting—Docetaxel—prostate cancer	0.000487	0.000854	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—APEX1—prostate cancer	0.000486	0.00138	CbGpPWpGaD
Trimetrexate—Rash—Docetaxel—prostate cancer	0.000483	0.000847	CcSEcCtD
Trimetrexate—Dermatitis—Docetaxel—prostate cancer	0.000482	0.000846	CcSEcCtD
Trimetrexate—Confusional state—Doxorubicin—prostate cancer	0.000482	0.000845	CcSEcCtD
Trimetrexate—DHFR—Metabolism—B4GALT4—prostate cancer	0.000481	0.00137	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—HPGD—prostate cancer	0.000481	0.00137	CbGpPWpGaD
Trimetrexate—Asthenia—Prednisone—prostate cancer	0.000474	0.000831	CcSEcCtD
Trimetrexate—Vomiting—Capecitabine—prostate cancer	0.000471	0.000827	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CCND2—prostate cancer	0.000469	0.00133	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Doxorubicin—prostate cancer	0.000468	0.00082	CcSEcCtD
Trimetrexate—Rash—Capecitabine—prostate cancer	0.000468	0.00082	CcSEcCtD
Trimetrexate—Pruritus—Prednisone—prostate cancer	0.000467	0.000819	CcSEcCtD
Trimetrexate—Dermatitis—Capecitabine—prostate cancer	0.000467	0.000819	CcSEcCtD
Trimetrexate—DHFR—Disease—LDHB—prostate cancer	0.000459	0.0013	CbGpPWpGaD
Trimetrexate—DHFR—Disease—RPL12—prostate cancer	0.000459	0.0013	CbGpPWpGaD
Trimetrexate—Nausea—Docetaxel—prostate cancer	0.000455	0.000798	CcSEcCtD
Trimetrexate—DHFR—Metabolism—TNFRSF21—prostate cancer	0.000452	0.00128	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CHEK2—prostate cancer	0.000447	0.00127	CbGpPWpGaD
Trimetrexate—Fatigue—Epirubicin—prostate cancer	0.000445	0.000781	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—MYC—prostate cancer	0.000444	0.00126	CbGpPWpGaD
Trimetrexate—Nausea—Capecitabine—prostate cancer	0.00044	0.000772	CcSEcCtD
Trimetrexate—DHFR—Metabolism—CYP7B1—prostate cancer	0.00044	0.00125	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—MTAP—prostate cancer	0.00044	0.00125	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TCN2—prostate cancer	0.000435	0.00124	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—APEX1—prostate cancer	0.000435	0.00123	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SULT1E1—prostate cancer	0.000429	0.00122	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SRD5A1—prostate cancer	0.000429	0.00122	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Epirubicin—prostate cancer	0.000426	0.000746	CcSEcCtD
Trimetrexate—Vomiting—Prednisone—prostate cancer	0.00042	0.000736	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—CCND2—prostate cancer	0.000419	0.00119	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—BRCA1—prostate cancer	0.000419	0.00119	CbGpPWpGaD
Trimetrexate—Rash—Prednisone—prostate cancer	0.000416	0.00073	CcSEcCtD
Trimetrexate—Dermatitis—Prednisone—prostate cancer	0.000416	0.000729	CcSEcCtD
Trimetrexate—Fatigue—Doxorubicin—prostate cancer	0.000412	0.000722	CcSEcCtD
Trimetrexate—DHFR—Metabolism—ACSL4—prostate cancer	0.000409	0.00116	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—HSD17B3—prostate cancer	0.000409	0.00116	CbGpPWpGaD
Trimetrexate—Body temperature increased—Epirubicin—prostate cancer	0.000408	0.000716	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—TYMS—prostate cancer	0.000403	0.00115	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Doxorubicin—prostate cancer	0.000394	0.00069	CcSEcCtD
Trimetrexate—Nausea—Prednisone—prostate cancer	0.000392	0.000688	CcSEcCtD
Trimetrexate—DHFR—Metabolism—UMPS—prostate cancer	0.000392	0.00111	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PHGDH—prostate cancer	0.000392	0.00111	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ARG2—prostate cancer	0.000392	0.00111	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—LDHB—prostate cancer	0.000385	0.00109	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—BRCA2—prostate cancer	0.000379	0.00108	CbGpPWpGaD
Trimetrexate—Body temperature increased—Doxorubicin—prostate cancer	0.000378	0.000662	CcSEcCtD
Trimetrexate—DHFR—Metabolism—CYP3A5—prostate cancer	0.000378	0.00107	CbGpPWpGaD
Trimetrexate—Asthenia—Epirubicin—prostate cancer	0.000371	0.00065	CcSEcCtD
Trimetrexate—DHFR—Disease—GSTO1—prostate cancer	0.00037	0.00105	CbGpPWpGaD
Trimetrexate—Pruritus—Epirubicin—prostate cancer	0.000366	0.000641	CcSEcCtD
Trimetrexate—DHFR—Metabolism—TCN2—prostate cancer	0.000365	0.00104	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—UCP3—prostate cancer	0.000365	0.00104	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PDHA1—prostate cancer	0.000365	0.00104	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GSTA3—prostate cancer	0.000365	0.00104	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—TYMS—prostate cancer	0.000361	0.00102	CbGpPWpGaD
Trimetrexate—DHFR—Disease—LRP2—prostate cancer	0.000355	0.00101	CbGpPWpGaD
Trimetrexate—DHFR—Disease—P4HB—prostate cancer	0.000348	0.000989	CbGpPWpGaD
Trimetrexate—DHFR—Disease—RPL10—prostate cancer	0.000348	0.000989	CbGpPWpGaD
Trimetrexate—DHFR—Disease—EIF2AK2—prostate cancer	0.000348	0.000989	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—HSD3B1—prostate cancer	0.000348	0.000988	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SLC22A3—prostate cancer	0.000348	0.000988	CbGpPWpGaD
Trimetrexate—Asthenia—Doxorubicin—prostate cancer	0.000343	0.000601	CcSEcCtD
Trimetrexate—DHFR—Disease—HIST1H2BG—prostate cancer	0.000342	0.00097	CbGpPWpGaD
Trimetrexate—Pruritus—Doxorubicin—prostate cancer	0.000338	0.000593	CcSEcCtD
Trimetrexate—DHFR—Metabolism—TBXAS1—prostate cancer	0.000334	0.000947	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GSTA4—prostate cancer	0.000334	0.000947	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HIST1H4H—prostate cancer	0.00033	0.000937	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NPPA—prostate cancer	0.00033	0.000937	CbGpPWpGaD
Trimetrexate—Vomiting—Epirubicin—prostate cancer	0.000328	0.000576	CcSEcCtD
Trimetrexate—Rash—Epirubicin—prostate cancer	0.000326	0.000571	CcSEcCtD
Trimetrexate—Dermatitis—Epirubicin—prostate cancer	0.000325	0.00057	CcSEcCtD
Trimetrexate—DHFR—Metabolism—GSTA2—prostate cancer	0.000325	0.000923	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SULT1A1—prostate cancer	0.000321	0.000912	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ABCG5—prostate cancer	0.000321	0.000912	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—TERT—prostate cancer	0.000314	0.000892	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GSTA1—prostate cancer	0.000314	0.000891	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GSTO1—prostate cancer	0.00031	0.000881	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—HSD3B2—prostate cancer	0.00031	0.000881	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—NAT2—prostate cancer	0.00031	0.000881	CbGpPWpGaD
Trimetrexate—Nausea—Epirubicin—prostate cancer	0.000307	0.000538	CcSEcCtD
Trimetrexate—Vomiting—Doxorubicin—prostate cancer	0.000304	0.000533	CcSEcCtD
Trimetrexate—Rash—Doxorubicin—prostate cancer	0.000301	0.000528	CcSEcCtD
Trimetrexate—Dermatitis—Doxorubicin—prostate cancer	0.000301	0.000528	CcSEcCtD
Trimetrexate—DHFR—Metabolism—PLCB2—prostate cancer	0.000297	0.000844	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—LRP2—prostate cancer	0.000297	0.000844	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP2C18—prostate cancer	0.000297	0.000844	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—P4HB—prostate cancer	0.000292	0.000828	CbGpPWpGaD
Trimetrexate—Nausea—Doxorubicin—prostate cancer	0.000284	0.000498	CcSEcCtD
Trimetrexate—DHFR—Metabolism—SLC22A1—prostate cancer	0.000284	0.000805	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—ATM—prostate cancer	0.000282	0.000802	CbGpPWpGaD
Trimetrexate—DHFR—Disease—B2M—prostate cancer	0.000281	0.000797	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TGFBR1—prostate cancer	0.000281	0.000797	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SULT2A1—prostate cancer	0.000276	0.000785	CbGpPWpGaD
Trimetrexate—DHFR—Disease—RPS19—prostate cancer	0.000276	0.000784	CbGpPWpGaD
Trimetrexate—DHFR—Disease—AKR1C3—prostate cancer	0.000276	0.000784	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PRKACB—prostate cancer	0.000275	0.00078	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—MED12—prostate cancer	0.000272	0.000772	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GNG5—prostate cancer	0.00027	0.000766	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PPP3CA—prostate cancer	0.000268	0.00076	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—NCOA3—prostate cancer	0.00026	0.000738	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PRKCZ—prostate cancer	0.000259	0.000735	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CALR—prostate cancer	0.000254	0.000722	CbGpPWpGaD
Trimetrexate—DHFR—Disease—FGFR4—prostate cancer	0.00025	0.00071	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PARP1—prostate cancer	0.00025	0.00071	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—HPGDS—prostate cancer	0.000248	0.000704	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CALCA—prostate cancer	0.000247	0.000702	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP2C19—prostate cancer	0.000246	0.0007	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GSTT1—prostate cancer	0.00024	0.000683	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ACHE—prostate cancer	0.00024	0.000683	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP2A6—prostate cancer	0.000238	0.000675	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HSPA1A—prostate cancer	0.000237	0.000673	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—AKR1C3—prostate cancer	0.000231	0.000657	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PRKACB—prostate cancer	0.00023	0.000653	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP17A1—prostate cancer	0.000228	0.000646	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CASP9—prostate cancer	0.000227	0.000645	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PRKCQ—prostate cancer	0.00022	0.000625	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—NCOA2—prostate cancer	0.000217	0.000616	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN1B—prostate cancer	0.000213	0.000604	CbGpPWpGaD
Trimetrexate—DHFR—Disease—FGF10—prostate cancer	0.000209	0.000594	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MDM2—prostate cancer	0.000208	0.000592	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SLC5A5—prostate cancer	0.000207	0.000588	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CCND1—prostate cancer	0.000203	0.000577	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP2E1—prostate cancer	0.000202	0.000574	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—NQO1—prostate cancer	0.0002	0.000567	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TGFBR2—prostate cancer	0.000199	0.000565	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—TH—prostate cancer	0.000197	0.000559	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN1A—prostate cancer	0.000196	0.000558	CbGpPWpGaD
Trimetrexate—DHFR—Disease—ITPR1—prostate cancer	0.000196	0.000556	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP3A4—prostate cancer	0.000195	0.000553	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP1B1—prostate cancer	0.000192	0.000544	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN1B—prostate cancer	0.00019	0.00054	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—EP300—prostate cancer	0.000187	0.000531	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GGT1—prostate cancer	0.000186	0.000527	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—NCOA1—prostate cancer	0.000183	0.000519	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CCND1—prostate cancer	0.000182	0.000516	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP19A1—prostate cancer	0.00018	0.000511	CbGpPWpGaD
Trimetrexate—DHFR—Disease—LPL—prostate cancer	0.000179	0.00051	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PDGFRB—prostate cancer	0.000178	0.000505	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN1A—prostate cancer	0.000176	0.000499	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—RXRA—prostate cancer	0.000174	0.000494	CbGpPWpGaD
Trimetrexate—DHFR—Disease—ERCC2—prostate cancer	0.000172	0.000488	CbGpPWpGaD
Trimetrexate—DHFR—Disease—ERBB3—prostate cancer	0.000168	0.000478	CbGpPWpGaD
Trimetrexate—DHFR—Disease—FGFR2—prostate cancer	0.000168	0.000477	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—COMT—prostate cancer	0.000167	0.000475	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—EP300—prostate cancer	0.000167	0.000475	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GSTP1—prostate cancer	0.000167	0.000473	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ITPR1—prostate cancer	0.000164	0.000466	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—MYC—prostate cancer	0.000163	0.000463	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MTHFR—prostate cancer	0.000162	0.000459	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TERT—prostate cancer	0.000161	0.000458	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—TYMS—prostate cancer	0.000155	0.00044	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HIF1A—prostate cancer	0.000154	0.000438	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GSTM1—prostate cancer	0.000153	0.000435	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—LPL—prostate cancer	0.00015	0.000427	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CAV1—prostate cancer	0.000149	0.000423	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MYC—prostate cancer	0.000146	0.000414	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP1A1—prostate cancer	0.000145	0.000412	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ERCC2—prostate cancer	0.000144	0.000409	CbGpPWpGaD
Trimetrexate—DHFR—Disease—BAD—prostate cancer	0.00014	0.000398	CbGpPWpGaD
Trimetrexate—DHFR—Disease—APC—prostate cancer	0.000136	0.000386	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—MTHFR—prostate cancer	0.000135	0.000384	CbGpPWpGaD
Trimetrexate—DHFR—Disease—IRS1—prostate cancer	0.000134	0.000381	CbGpPWpGaD
Trimetrexate—DHFR—Disease—EGF—prostate cancer	0.000134	0.000381	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PPARA—prostate cancer	0.000133	0.000377	CbGpPWpGaD
Trimetrexate—DHFR—Disease—GSK3B—prostate cancer	0.00013	0.00037	CbGpPWpGaD
Trimetrexate—DHFR—Disease—INS—prostate cancer	0.000129	0.000365	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CREBBP—prostate cancer	0.000126	0.000358	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CAV1—prostate cancer	0.000125	0.000355	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MAP2K1—prostate cancer	0.00012	0.000341	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—TP53—prostate cancer	0.00012	0.00034	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CD—prostate cancer	0.000119	0.000339	CbGpPWpGaD
Trimetrexate—DHFR—Disease—SERPINE1—prostate cancer	0.000118	0.000335	CbGpPWpGaD
Trimetrexate—DHFR—Disease—FGF2—prostate cancer	0.000114	0.000325	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CG—prostate cancer	0.000114	0.000323	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NOS3—prostate cancer	0.000113	0.00032	CbGpPWpGaD
Trimetrexate—DHFR—Disease—JAK2—prostate cancer	0.00011	0.000311	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—INS—prostate cancer	0.000108	0.000306	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MDM2—prostate cancer	0.000107	0.000304	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CREBBP—prostate cancer	0.000105	0.000299	CbGpPWpGaD
Trimetrexate—DHFR—Disease—ERBB2—prostate cancer	0.000105	0.000299	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CB—prostate cancer	0.000104	0.000295	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PTGS2—prostate cancer	0.000103	0.000293	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CD—prostate cancer	0.0001	0.000284	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CDKN1B—prostate cancer	9.76e-05	0.000277	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—NOS3—prostate cancer	9.44e-05	0.000268	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CTNNB1—prostate cancer	9.22e-05	0.000262	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CDKN1A—prostate cancer	9.01e-05	0.000256	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PTEN—prostate cancer	8.99e-05	0.000255	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CB—prostate cancer	8.71e-05	0.000247	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PTGS2—prostate cancer	8.63e-05	0.000245	CbGpPWpGaD
Trimetrexate—DHFR—Disease—EP300—prostate cancer	8.57e-05	0.000243	CbGpPWpGaD
Trimetrexate—DHFR—Disease—SRC—prostate cancer	8.34e-05	0.000237	CbGpPWpGaD
Trimetrexate—DHFR—Disease—STAT3—prostate cancer	8.04e-05	0.000228	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PTEN—prostate cancer	7.53e-05	0.000214	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MYC—prostate cancer	7.47e-05	0.000212	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TGFB1—prostate cancer	7.45e-05	0.000212	CbGpPWpGaD
Trimetrexate—DHFR—Disease—EGFR—prostate cancer	7.31e-05	0.000208	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—EP300—prostate cancer	7.18e-05	0.000204	CbGpPWpGaD
Trimetrexate—DHFR—Disease—KRAS—prostate cancer	6.9e-05	0.000196	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CA—prostate cancer	6.34e-05	0.00018	CbGpPWpGaD
Trimetrexate—DHFR—Disease—IL6—prostate cancer	5.62e-05	0.000159	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CA—prostate cancer	5.31e-05	0.000151	CbGpPWpGaD
Trimetrexate—DHFR—Disease—AKT1—prostate cancer	5.18e-05	0.000147	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—AKT1—prostate cancer	4.34e-05	0.000123	CbGpPWpGaD
